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Peter J GoadsbyAsked to write upon the matters arising [1] from comments
[2] on an earlier contribution [3] is an unusual position that
has allowed debate around the beta version of the third
edition of the International Classification of Headache
Disorders, specifically its definition of hemicrania continua
[4]. The issue at hand is the extent to which further
experience and clinical science should allow the first
description of a syndrome to evolve over time. I am sorry
if my nuanced title left one’s correspondents of a mind
that I was expressing more than a general principle.
Regarding our development of a placebo-controlled
indomethacin test for hemicrania continua [5], the
purpose of the evolution was to introduce the scientific
discipline of a control arm. It is generally accepted that
the use of placebo can be traced to widely available texts
of a slightly older vintage [6], over which priority in
many ways would be jejune at best. The authors state
“indomethacin is potentially a harmful drug”, a splendid
justification for careful placebo-controlled assessment
of the patient before longer term medicine exposure.
Furthermore, the authors argue for an absolute limit on
daily use of indomethacin at 200 mg per day. One recom-
mends your correspondents consider the concept of a
normal distribution, which predicts a rigid upper limit will
fail to capture some cases. Now if there was a biological
basis for such a rule this would be wonderful, however,
since there is not, the dated, perhaps mid-twentieth
century concept that “it is because we say so…” might
usefully transform to a more objective advisory evolved
through clinical science. Perhaps not recognized by your
correspondents, the placebo-controlled indomethacin test
is simply a way to bring order to study of the problem.
We saw no harm in our series, and would submit labeling
placebo control as not rational is, at best, a very curious
use of the term.Correspondence: peter.goadsby@kcl.ac.uk
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in any medium, provided the original work is pOn the subject of the cranial autonomic features, I am
not sure why seven features as we have reported [5]
constitute a “heap”, which I think is probably not the
collective noun for a list of cranial autonomic features,
when six, as the authors identified [7], is untouchably
canonical? Moreover, by taking a very careful history,
identifying the symptoms is perhaps easier if one is
aware of the literature as it stood. The frequency difference
seems utterly predictable by the passage of time and
experience of enquiry. Your correspondents identify a
human factor in the varying frequency of symptoms;
one might christen that as bogus, although one might
also conclude a less dogmatic, open scientific approach, as
we have applied, is likely to see more than a less flexible
form of rigid enquiry. The authors refer to the added
cranial autonomic features being obligatory; the phrase- at
least one [4] does not make anything obligatory.
Your correspondents seems content with the concept
of adding features [8]; the essential issue seems to be
what defines the “frame”. I would suggest data derived
substantially from a placebo-controlled study should
take precedence over opinion, no matter how exalted
the source.
Regarding non-indomethacin unilateral headache, we
have certainly seen this. I am sorry if I was not clear when
I said “non is not an option” referring to an indomethacin
response in hemicrania continua. What I should have
spelt out is that for ICHD-III-beta [4], if there is no indo-
methacin response, the diagnosis is not made. I was not
commenting upon the acronym itself. Unilateral headache
without an indomethacin effect deserves careful study; this
will require use of placebo, careful phenotyping and an
open mind- acronym creation may serve those masters
when the subject is better understood.
Your correspondents’ comment that the remark- I would
submit the diagnosis has not changed- is meaningless and
uninformative. The statement has a clear meaning, or the
authors would not have commented to the meaning, and aspen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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seem both to have understood and been informed, if
not pleased.
Lastly, your correspondents state the female Case One
as described [9] would not have hemicrania continua by
ICHD-III-beta. That patient has unilateral headache (A), it
was present for more than three months with fluctuations
(B). She “sometimes lay down in bed quietly” (C-2- by
behavior). They report “indomethacin completely abolished
her headache” (D), and she has no findings of abnormal
neurology on examination or investigation, nor does she
have another diagnosis to explain her problem (E). The
patient described in 1984 had hemicrania continua [9],
application of ICHD-III-beta [4] diagnoses hemicrania
continua. One invites the correspondents to re-read
ICHD-III-beta and criticise what is wrong, rather than
bloviate by less than attentive application of the criteria.
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